EPOXYPREGNADIENES, HYDROXYPREGNATRIENES, PROCESS FOR THEIR PREPARATION AND PROCESS FOR THEIR CONVERSION TO PRECURSORS OF USEFUL ANTI-INFLAMMATORY AGENTS

Abstract: 21-Hydroxypregna-1,4,17(20)- trien- 3-one 21- acylates are converted to novel 17α, 20α-epoxypregna-1,4- dien-3-one 21-acylates (I) using a peracid, compounds I are converted to novel 21-hydroxypregna-1,4,16- trien-3-one 21-acylates (II) with a hydrogen halide, and compounds II are converted to 20, 21-dihydroxypregna-1,4,16- trien-3-ones (III) by hydrolysis. Compounds III are useful intermediates in the production of anti-inflammatory agents.

Description: EPOXYPREGNADIENES, IJYDROXYPREGNATRIENES, PROCESS FOR TliETR PREPARATION AND PROCESS FOR THEIR CONVERSION TO PRECUR3RS OF USEFUL ANTI-INFLAMMATORY AGENTS This invention relates to novel 17a, 20aepoxypregna-1,4-dien-3-one 21-acylates (I) and novel 21hydroxypregna-1,4,16-trien-3-one 21-acylates (II), the conversion of the formula I to the formula II compounds, the preparation of the formula I compounds from 21-hydroxypregna-1,4,17(20)-trien-3-one 21-acylates (0), and the preparation of 2D,21-dihydroxypregna-1,4,16-trien-3-ones (III) by hydrolysis of the formula II compounds. The formula III compounds are useful as intermediates in the production of anti-inflammatory agents. It will be appreciated that the preparation of the formula II compounds from the formula 0 compounds via the formula I epoxides involves a change in position of a carbon-carbon double bond. U.S. Patent Specification No. 3,444,216 discloses 11S,2l-dihydroxypregn-4-en-3-one. U.S. Patent Specification No. 3,375,261 discloses 21-acylated steroids having a double bond. The reaction of a ketone with a peracid is well known in the art and has been termed the Eaeyer- Villiger reaction (the oxidation of ketones with peracids). In the Baeyer-Villiger reaction, an oxygen atom is inserted between the carbonyl group and the alkyl portion of the ketone, thereby forming an ester. In the case of a cyclic ketone, such as a 3-keto steroid,it is well known that the resulting product is the corresponding A-ring lactone, as is shown in Organic Reactions 9, 73 (1957) and J. Med. Pharm. Chem. 5, 714 (1962). Page 79 of the former reference shows the exact problem that may be anticipated when epoxidising a carbon-carbon double bond in a 3-keto steroid while wishing not to affect the A-ring. Page 715 of the latter reference discloses the Baeyer-Villiger reaction when the reactant is a A4-3-keto steroid. The lactone and subsequent side reaction products are formed. It might therefore be anticipated that a not insignificant amount of Bacyer-illiger product (lactone) would be obtained when any 3-keto steroid or,more specifically, when a A4-3-keto or a Als4-3-keto steroid was reacted with a peracid. In contrast, U.S. Patent Specification No. 3,876,633 discloses oxidation of a A17(20)-steroid to the corresponding 17a,ZOa-epoxy-steroid in a 97 yield (weight). This is not unexpected because the steroid used in this process did not have a ketone group in ring A and therefore no side reaction (Baeyer-Villiger reaction) was possible. Surprisingly it has been found that, when a compound of formula 0 is reacted with a peracid, a formula I compound is formed and the amount of any S.aeyer- Villiger reaction products can be very low. It is nown that the position of carboncarbon double bonds in steroids can be changed. For example, U.S. Patent Specification No. 3,725,392 discloses a process for producing various 9a-fluoro-16B-alkylprednisolones, including 9a-fluoro-16ss-methylprednisolone (betamethasone), which are known to be highly active anti-inflammatory agents. The prednisolone type steroids have a A 3-keto A ring. This specification discloses that the process can be performed on a prednisolone-type compound or on a cortisone-type (E -3-keto) compound, the A double bond being put in later. The first 2 steps of the disclosed process comprise the transformation of a llss,21-dihydrox > - pregna-4,17(20)-dien-3-one to a llss,20,21-trihydroxy- pregna-4,16-dien-3-one, using photosensitised oxygenation followed by reduction. Example 1 of this specification discloses that, starting with 165.2 g (0.5 molc) of the A17 (20) compound, 51.1 g (0.15 moles) of the A16-21-ol are obtained, a 30 ó chemical yield. U.S. Patent Specification No. 3,281,415 discloses the transformation of a 17(20)-olefinic steroid to the corresponding A16-20-keto steroid. Claim 20 claims a process of producing compounds of formulae II and III of the present invention using photosensitised oxygenation. In column 30, at line 8, llss,20a,21-trihydroxy-1,4,16- pregnatrien-3-one 21-acetate is disclosed as a starting material for the preparation of the corresponding 20-keto compound, but -there is no indication of how tlie starting material might be prepared. German Specification No. 1,301,999 discloses a process for transforming a 17a,2Oa-epoxypregnane to a A16- 21-ol in about 9OOb yield by use of 1.82 equivalents of hydrogen bromide. The lOte impurity is the 17ss-bromide. Gcrman Specification No. 1,297,604 dicloses a process for transforming a A17(20)-pregnane into a A16 -21- ol by peracid oxidation of the A17(20)-pregnane to the corresponding 17a,20a-epoxide which is then reacted with hydrogen iodide to form a 17ss-iodide which is then transform- ed to the A16-21-o1. U.S. Patent Specification No. 4,089,852 discloses the preparation of 21-hydroxpegn-16-en-20-ones by alkylating a 17-keto steroid with a lithium reagent of the formula LiC(OR4)=CllOR3, thereby introducing, at the 17-position, a ss-hydroxy group and a -C(OR4)=CHOR3 group in the &alpha;-position, eliminating the 17B-hydroxy and hydrolysis ing the OR4 group. It is to be noted that this process does not involve the step-wise migration of a carbon-carbon double bond. Further, this process requircs an expensive lithium reagent. The claims are limited to the use of 17-keto steroids which do not have any other free keto function and the reaction is therefore apparently inapplic- able to 3-ketopregnanes. Surprisingly, we find that a formula I compound can be reacted to form a formula II compound in good yield, using only a low amount of a hydrogen halide and producing only a small amount of the 17B-halide, apparently without forming that compound as an intermediate. According to a first aspect of the present invention, a compound of formula II: EMI4.1 wherein R6 is hydrogen, methyl or fluorine; R11 is (3-hydroxy or oxo; and R21 is C13 alkyl or phenyl optionally substituted by up to 3 substituents independently selected from fluorine, chlorine, methyl, methoxy and nitro, is prepared by a process -which comprises reacting an epoxide of formula I: EMI4.2 wherein R6, R11 and R21 are as defined above, with hydrochloric or hydrobromic acid. According to a second aspect of the present invention, an epoxide of formula I as defined above is prepared by a process which comprises oxidising an olefin of formula 0: EMI5.1 wherein R6, R11 and R21 are as defined above, with at least one molar equivalent of a peracid. The compounds of formula I and II are novel and provide further aspects of this invention. A compound of formula II may be hydrolysed, using a base, to a compound of formula III: EMI5.2 wherein R6 and R11 are as defined above. In the formulae in this specification, the --- bond by which the R11 substituent is attached to the C ring of the steroids means that there is a single bond when R11 is (3-hydroxy and a double bond when R11 is oxo. The peracid oxidation of the 17(20) olefin of formula 0 to the 17a,20a-epoxide of formula I can be performed with virtually any peracid. The preferred peracids are peracetic, perpropionic, perbenzoic and m-chloroperbenzoic acid. The most preferred peracid is peracetic acid. Peracids (especially peracetic acid) are commercially available or may be readily prepared from the corresponding acid by known procedures. At least 1.0 equivalent of the peracid is required. Usually no more than 5.0 equivalents are used and it is preferred that about 1.5 equivalents of the peracid are used. The peracid oxidation can be performed in most non-polar solvents, such as methylene chloride, chloroform, toluene, cyclohexane and Skellysolve B (a mixture of isomeric hexanes). The reaction can be performed at a temperature of about OOCto to the reflux temperature of the particular solvent utilised. It is preferred that the reaction temperature is 20-25 C. At colder temperatures, the reaction proceeds slowly and, while the reaction proceeds faster at high temperatures, heating is required. At 20-25OC. the reaction is complete after stirring overnight. When the oxidation reaction is complete as measured by thin layer chromatography, any excess peracid is destroyed by an inorganic reducing agent such as sodium thiosulphate or sodium sulphite. The epoxide of formula I is opened by reaction with either hydrochloric or, preferably, hydrobromic acid. The amount of the acid is usually below 0.5 equivalents;the preferred amount is 0.03-0.05 equivalents. More than 0.05 equivalents of acid can be used but, the greater the amount of acid, the greater the likelihood of hydrolysis of the C21 ester and formation of the 176-halide. The epoxide opening is best performed in polar oxygenated solvents such as tetrahydrofuran (THF), dioxane or diethyl ether; THF is the preferred solvent. It is preferred that the polar oxygenated solvent is dry as less acid is then required. This reaction is preferably performed at 20-250C. although lower or higher temperatures will also work. The acid is best added slowly to the epoxide, in order to avoid side reactions. The hydrolysis of the formula I1 compound is performed utilising a strong base such as sodium hydroxide, potassium hydroxide, a methoxide, an ethoxide, sodium carbonate, potassium carbonate, sodium bicarbonate or potassium bicarbonate. The hydrolysis reaction is performed in a polar solvent such as acetone and/or alcohol. At 20-25 C. the reaction is complete in about 30 minutes. For weaker bases the reaction time will be a little longer. In the present invention, R6 is preferably hydrogen, R11 is preferably ss-hydroxy and R21 is preferably methyl. The invention is particularly suitable for the preparation of llss,20,21-trihydroxypregna-1,4,16-trien-3- one (III) via llss,20,21-trihydroxypregna-1,4,16-trien-3- one 21-acetate (II), 11B,21-dihydroxy-17a,20a-epoxypregna- l,4-dien-3-one 21-acetate (I) and llss,21-dihydroxypregna- 1,4,17(20)-trien-3-one 21-acetate (O). The preferred compound of formula III is known from U.S. Patent Specification No. 3,725,392. Therefore the preferred compound of formula (III) is an important intermediate in the synthesis of 9a-±1uoro-166-methylprednisolone (betamethasone) which is an important anti-inflammatory steroid. The compounds of formulae I and II in which R6 is methyl and R11 is (3-hydroxy are therefore important intermediates in the synthesis of betamethasone. The following Examples illustrate the invention. Comparative Examples are provided for reference. In the Examples,TLC refers to thin-layer chromatography; THF refers to tetrahydrofuran; SSB refers to a mixture of isomeric hexanes;"saline"refers to an aqueous saturated sodium chloride solution; [a]D5 refers to the angle of rotation of plane polarised light (specific optical rotation) at 25 C. with the sodium D line (5893 R. Example 1 11ss,21-Dihydroxy-17&alpha;,20&alpha;-epoxypregna-1,4- dicn-3-one 21-acetate (I) 79.5 g. of llss,21-dihydroxypregna-1,4,17(20)- trien-3-one 21-acetate (formula O - see U.S. Patent Specification No. 2,842,569), 800 ml. of methylene chloride and 9.3 g. of anhydrous sodium acetate are stirred under nitrogen at 190C. Peracetic acid (40t,55ml.) is added to the mixture over a period of 10 minutes. The reaction mixture is stirred for hours at 20-25 0C. Sodium thiosulfate solution (15%, 200 ml) is added to destroy the excess peracetic acid. The mixture is then washed with aqueous sodium bicarbonate solution -(6%, 600 ml.) and a halfsaturated sodium chloride solution(250 ml.). The mixture is dried over magnesium sulfate and concentrated on a steam bath at 800C. at atmospheric pressure while replacing the methylene chloride with SSB. The mixture is concentrated to 250 ml., SSB (500 ml.) is added, the mixture is concentrated to 425 ml., SSB (300 ml.).is added and the mixture is concentrated to 425 ml. at 650C. The mixture is then cooled to 50C. and filtered. The solids are washed with SSB and dried under reduced pressure at 700C. to give the title compound, 81.86 g (98.7% chemical yield), m.p. 374 25 1850C; [&alpha;]D + 81.8 (chloroform). Example 2 11B,21-Dihydroxy-17a,20a-epoxypregna-1,4 dien-3-one 21-acetate (I) 11ss,21-Dihydroxypregna-1,4,17(20)-trien-3- oue 21- acetate (1 k, sodium acetate (117 g.) and methylene chloride (10.1) are stirred at 20 C. Peracetic acid (40t 692 ml.) is added over a period of an hour and the mixture is stirrred overnight at 200C. The reaction mixture is washed with anhydrous sodium thiosulfate (15t,2.83 1.). The organic phase is then washed with aqueous sodium bicarbonate (9%, 6.5 1.) followed by a wash with an aqueous sodium chloride solution (13%, 3.1 1.). The methylene chloride is then replaced by SSB by the following procedure: the organic phase is concentrated at atmospheric pressure to about 3.1 1., SSE (4.3 1.) is added, the mixture is again concentrated at atmospheric pressure to about 5.3 1., SSB (2.6 1.) is added and the mixture once again concentrated to about 5.3 1. The mixture is then cooled and filtered to obtain the title compound, 1.03 kg. (98.7"b chemical yield). Comparative Example A A solution of llss,21-dihydroxypregna-4,17- (20)-dien-3-one 21-acetate (42.0 g.) in methylene chloride (450 ml) is stirred with cooling at OOC. while a mixture of m-chloroperbenzoic acid (26.4 g., 80.2% pure) is added over a period of 13 minutes. The mixture is stirred at 0-50C for 90 minutes and then at 20-25 C. for 16 hours. The reaction mixture is washed with a sodium bicarbonate solution (5%) and then with water. The methylene chloride solution is dried over anhydrous magnesium sulfate and the organic diluent is removed under reduced pressure while heating in a water bath at 50-600C. The residue is crystallised from acetone to give 17a,20a-epoxy-llB,21-dihydroxypregn- 4-en-3-one 21 acetate (34.314 g.). A second crop of crystals was obtained (3.0 g.) containing about 50% of the desired epoxide. The total yield is about 35.81 g.or 81.8%. The TLC (ethyl acetate/benzene; 45/55 v/v) of the mother liquid shows a substantial amount of a Baeyer-Villiger by-product as might be expected on the basis of what is known about reaction of ketones (A4- 3-keto function of ring A) with peracids. Example 3 llss,20,21-Trihydroxypregna-1,4,16-trien-3- one 21-acetate (II) 11B,21-Dihydroxy-17a,20a-epoxypregna-1,4 dien-3-one 21-acetate (Example 1, 20 g) in T}1F (700 ml.) is stirred at 23.5 C. A solution of hydrogen bromide (48%, 0.31 ml.) in TiiF (100 ml.) is added to the mixture over a period of 38 minutes. The reaction temperature increases from 23.50 to 25.50C during the hydrogen bromide addition. The mixture is stirred for 20 minutes and then concentrated under reduced pressure at 43 Cto an oil. The oil is dissolved in methylene chloride (50 ml.) at reflux. The mixture is concentrated on a steam bath at atmospheric pressure while rcplacing the methylene chloride with diethyl ether. lten all the methylene chloride is removed the mixturc is stirred at 20-250C. for 3 hours and filtered. The solids are washed with diethyl ether and dried under reduced pressure at 700C.to give the title compound, 18.1 g. (90.5% chemical yield), m.p. 121.5-l35.50C; t]D25 +56.30 (chloroform). Example 4 11S,20,21-Trihydroxypregna-1,4,16-trien-3- one 21-acetate (II) llss,21-Dihydroxy-17a,20a-epoxypregna-1,4- dien-3-one 21-acetate (Example 2, 1.0 kg3 in THF (33 kg.) is stirred at 250C. Hydrogen bromide (48%, 15 mlJ in THF (4.4 1.) is added over a period of one hour and the mixture is stirred for another hour at 25-300C. The mixture is concentrated under reduced pressure to 2 1., acetone (6.3 kg.) is added and the mixture is kept at 20-25 C. The title compound may be isolated, if so desired, by the procedure of Example 3. Comparative Example B Following the procedures of Examples 1 and 3, 11(3,2l-dihydroxypregna-l,4,l7(20)-trien-3-one, i.e. the non-acylated compound, was converted to 11ss,20,21-trihydrxy- pregna-1.4,16-trien-3-one, compounds disclosed in U.S. Patent Specification No. 3,725,392, at temperatures of 150 C. and 30 C.(23.5-25.5 C. was used in Example 3 above). At 0 15 C. the overall chemical yield was 49.5t and was 74.2% at 30 C. While the yield is clearly temperature dependent, the overall chemical yield of Example 1 and 3 above was about 89%. Example 5 llss,20,21-Trihydroxypregna-1,4,16-trien- 3-one (III) 11ss,20,21-Trihydroxypregna-1,4,16-trien- 3-one 21-acetate (Example 4, 16.5 g is dissolved in acetone (170 ml.) and stirred at 20-250C. Methanol (10 ml.) and sodium methoxide in methanol (25%, 1.25 ml.) are added and the mixture is stirred for 30 minutes. Acetic acid is added to neutralise the base, the mixture is concentrated under reduced pressure with a little heat and the title compound is obtained by crystallisation. Example 6 llss,20,21-Trihwdroxypregna-1,4,16-trien-3- one (III). Methanol (0.5 1.) and sodium methoxide (25% in methanol, 75 ml.) are added to 118, 20,21-trihydroxypregna1,4,16-trien-3-one 21-acetate (Example 3) in acetone and the mixture is stirred for 30 minutes at 20-25 C. The title compound is obtained by the work-up procedure of Example 5.

Claims: CLAIMS 1. A process for preparing a compound of formula II: EMI12.1 wherein R6 is hydrogen1 methyl or fluorine; R11 is (3--hydroxy or oxo; and R21 is C13 alkyl or phenyl optionally substitut- ed by up to 3 substituents independently selected from fluorine, chlorine, methyl methoxy and nitro, the process comprising reacting an epoxide of formula I: EMI12.2 wherein R6, Rll and R21 are as defined above, with hydrochloric acid or hydrobromic acid. 2. A process according to claim 1 wherein the acid is hydrobromic acid. 3. A process according to claim 1 or claim 2 wherein the epoxide of formula I is prepared by oxidising an olefin of formula 0: EMI13.1 wherein R6, R11 and R21 are as defined in claim 1, with at least one molar equivalent of a peracid. 4. A process according to claim 3 wherein the peracid is selected from peracetic acid, perpropionic acid, perbenzoic acid and m-chloroperbenzoic acid. 5. A compound of formula II when prepared by a process according to any preceding claim. 6. llss,20,21-Trihydroxypregna-1,4,16-trien-3- one 21-acetate when prepared by a process according to any of claims 1 to 4. 7. A compound of formula II: EMI13.2 wherein R6, R11 and R21 are as defined in claim 1. 8. llss,20,21-Trihydroxypregna-1,4,16-trien-3- one 21-acetate. 9. A process for preparing a compound of formula III: EMI14.1 wherein R6 and R11 are as defined in claim, which comprises hydrolysing, with a base, a compound of formula II as claimed in any of claims 5 to 8. 10. A process according to claim 9 wherein the base is selected from methoxides, ethoxides, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate. 11. A compound of formula : EMI14.2 wherein R6, R11 and R21 are as declined in claim 1. 12. llss,21-Dihydroxy-17a,20a-epoxypregna-1,4- dien-3-one 21-acetate. 13. A process for preparing a compound as claimed in claim 11 or claim 12 which comprises oxidising an olefin of formula 0 as defined in claim 3 with a peracid.

Inventors: SHEPHARD, KENNETH PAUL
Applicants: THE UPJOHN COMPANY
Application year: 1979
Main classification: C07J13
IPC codes: C07J21, C07J13